“This study showed that people with glioblastoma, a particularly devastating and aggressive cancer without many treatment options, lived significantly longer without their disease worsening when Avastin was added to radiation and temozolomide chemotherapy”

No new safety findings were observed in the AVAglio study, and adverse events were consistent with those seen in previous trials of Avastin across tumor types for approved indications. Full data from the AVAglio study will be submitted for presentation at an upcoming medical meeting.

Avastin is currently approved in the United States for the treatment of adults with glioblastoma who have progressive disease following prior therapy. In glioblastoma, it is approved for use as a single therapy and not in combination with other therapies. The effectiveness of Avastin is based on improvement in objective response rate. Currently, no data are available from randomized controlled trials demonstrating improvement in disease related symptoms or increased survival with Avastin in glioblastoma. The approval was granted under the U.S. Food and Drug Administration’s (FDA) accelerated approval program.

“This study showed that people with glioblastoma, a particularly devastating and aggressive cancer without many treatment options, lived significantly longer without their disease worsening when Avastin was added to radiation and temozolomide chemotherapy,” said Hal Barron, M.D., chief medical officer and head, Global Product Development.

Roche and Genentech plan to discuss these Phase III results with global regulatory authorities, including the European Medicines Agency (EMA) and FDA.

About the AVAglio Study

AVAglio is a Phase III, randomized, double-blind, placebo controlled trial that assessed the efficacy and safety profile of Avastin in combination with radiation and temozolomide chemotherapy following surgery or biopsy in patients with newly diagnosed glioblastoma. Patients were randomized to receive either:

• Avastin plus radiation and temozolomide chemotherapy for six weeks followed by a four-week break. Patients then received Avastin and temozolomide for up to six cycles, followed by Avastin alone until disease progression.
• Radiation, temozolomide and placebo for six weeks followed by a four-week break. Patients then received temozolomide and placebo for up to six cycles, followed by placebo until disease progression.

The co-primary endpoints of the study were OS and PFS as assessed by trial investigators. Secondary endpoints included one- and two-year survival rates, PFS as assessed by an independent review committee, safety profile and quality of life measures.

About Glioblastoma

Glioma (cancer of the glial cells) is the most common type of malignant primary brain tumor (a tumor that originates in the brain), accounting for approximately one-third of all cases diagnosed. Glioblastoma (or glioblastoma multiforme) is the most common and the most aggressive type of glioma, affecting approximately 10,000 people per year in the United States. Glioblastoma is a rational therapeutic target for Avastin as these tumors have among the highest levels of vascular endothelial growth factor (VEGF) of any solid tumor.

About Avastin

Avastin is a prescription-only medicine that is a solution for intravenous infusion. It is a biologic antibody designed to specifically bind to a protein called VEGF that plays an important role throughout the lifecycle of the tumor to develop and maintain blood vessels, a process known as angiogenesis. Avastin is designed to interfere with the tumor blood supply by directly binding to the VEGF protein to prevent interactions with receptors on blood vessel cells. The tumor blood supply is thought to be critical to a tumor's ability to grow and spread in the body (metastasize). For more information about angiogenesis, visit http://www.gene.com.

BOXED WARNINGS and Additional Important Safety Information

People receiving Avastin may experience side effects. In clinical trials, some people treated with Avastin experienced serious and sometimes fatal side effects, including:

Gastrointestinal (GI) perforation: Treatment with Avastin can result in the development of a serious side effect called GI perforation, which is the development of a hole in the stomach, small intestine, or large intestine. In clinical trials, this event occurred in more people who received Avastin than in the comparison group (2.4 percent to 0.3 percent). In some cases, GI perforation resulted in fatality. Avastin therapy should be permanently stopped if GI perforation occurs.

Surgery and wound healing problems: Treatment with Avastin can lead to slow or incomplete wound healing (for example, when a surgical incision has trouble healing or staying closed). In some cases, this event resulted in fatality. Surgery and wound healing problems occurred more often in people who received Avastin than in the comparison group. In a controlled clinical trial, in patients with metastatic colorectal cancer who had surgery during the course of treatment, the incidence of wound healing complications, including serious and fatal complications, was 15 percent for patients who received Avastin and four percent for patients who did not receive Avastin.

Avastin therapy should not be started for at least 28 days after surgery and until the surgical wound is fully healed. The length of time between stopping Avastin and having voluntary surgery without the risk of wound healing problems following surgery has not been determined. Treatment with Avastin should be stopped at least 28 days before voluntary surgery and in people with wound healing problems following surgery that require medical treatment. Treatment with Avastin should be stopped in patients with slow or incomplete wound healing.

Severe bleeding: Treatment with Avastin can result in serious or fatal bleeding, including coughing up blood, bleeding in the stomach, vomiting of blood, bleeding in the brain, nosebleeds and vaginal bleeding. These events occurred up to five times more often in people who received Avastin compared to patients who received only chemotherapy. Across cancer types, 1.2 percent to 4.6 percent of people who received Avastin experienced severe to fatal bleeding. People who have recently coughed up blood (greater than or equal to a half teaspoon of red blood) or have serious bleeding should not receive Avastin. Treatment with Avastin should be permanently stopped if serious bleeding occurs.

In clinical trials for different cancer types, there were additional serious and sometimes fatal side effects that occurred in more people who received Avastin than in those in the comparison group. The formation of an abnormal passage from parts of the body to another part (non-GI fistula formation) was seen in 0.3 percent or less of people. Severe to life-threatening stroke or heart problems were seen in 2.6 percent of people. Too much protein in the urine that led to kidney problems was seen in less than one percent of people. Additional serious side effects that occurred in more people who received Avastin than those in the comparison group included severe to life-threatening high blood pressure, which was seen in five percent to 18 percent of people, and nervous system and vision disturbances (reversible posterior leukoencephalopathy syndrome), which was seen in less than 0.1 percent of people. Infusion reactions with the first dose of Avastin were uncommon and occurred in less than three percent of people, and severe reactions occurred in 0.2 percent of people. Avastin can cause fertility issues for women. Avastin could cause a woman’s ovaries to stop working and may impair her ability to have children.

Common side effects that occurred in more than 10 percent of people who received Avastin for different cancer types, and at least twice the rate of the comparison group, were nosebleeds, headache, high blood pressure, inflammation of the nose, too much protein in the urine, taste change, dry skin, rectal bleeding, tear production disorder, back pain, and inflammation of the skin (exfoliative dermatitis). Across all trials, treatment with Avastin was permanently stopped in 8.4 percent to 21 percent of people because of side effects.

Patients who are pregnant or thinking of becoming pregnant should talk with their doctor about the potential risk of loss of the pregnancy or the potential risk of Avastin to the fetus during and following Avastin therapy, and the need to continue an effective birth control method for at least six months following the last dose of Avastin.

Women should be advised to discontinue nursing or discontinue treatment with Avastin, taking into account the importance of Avastin to the mother.

Glioblastoma

In the glioblastoma clinical trial AVF3708g, the most common side effects in people who received Avastin alone were infection (occurred in 55 percent of people), tiredness (occurred in 45 percent of people), headache (occurred in 37 percent of people), high blood pressure (occurred in 30 percent of people), nosebleeds (occurred in 19 percent of people), and diarrhea (occurred in 21 percent of people). Some of these common side effects were severe to life-threatening or fatal: infection (occurred in 10 percent of people), tiredness (occurred in 4 percent of people), headache (occurred in 4 percent of people), high blood pressure (occurred in 8 percent of people), and diarrhea (occurred in 1 percent of people). Two fatalities were possibly related to Avastin: one from bleeding in the abdomen, and one from severely reduced white blood cell counts that led to infection.

People who received Avastin alone or Avastin plus irinotecan* (chemotherapy) experienced mild to life-threatening side effects including bleeding (occurred in 40 percent of people), nosebleeds (occurred in 26 percent of people), bleeding in the brain (occurred in 5 percent of people), high blood pressure (occurred in 32 percent of people), blood clots in the veins of the body (occurred in 8 percent of people), stroke or heart problems (occurred in 6 percent of people), surgery and wound healing problems (occurred in 6 percent of people), too much protein in the urine (occurred in 4 percent of people), the development of a hole in the stomach, small intestine, or large intestine (occurred in 2 percent of people), and nervous system and vision disturbances (occurred in 1 percent of people). People who received Avastin alone or Avastin plus irinotecan (chemotherapy) experienced severe to fatal side effects including bleeding (occurred in 2 percent of people), bleeding in the brain (occurred in 1 percent of people), high blood pressure (occurred in 5 percent of people), blood clots in the veins of the body (occurred in 7 percent of people), stroke or heart problems (occurred in 3 percent of people), surgery and wound healing problems (occurred in 3 percent of people), too much protein in the urine (occurred in 1 percent of people), and the development of a hole in the stomach, small intestine, or large intestine (occurred in 2 percent of people). Bleeding within the brain occurred in 8 of 163 people; 2 people had severe to life-threatening bleeding.

* Avastin is not approved for use for glioblastoma in combination with irinotecan.

For full Prescribing Information and Boxed WARNINGS on Avastin, please visit http://www.avastin.com.

About Genentech

Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

「衛星通信はグローバルな事業運営のほか、人道的活動や災害復旧活動においてますます重要なリソースになっています。現在、軌道上にある衛星と地上局の数は過去最多で、無線周波数環境は厳しい状況にあります。世界中のユーザーすべてが信頼できる通信サービスを確実に利用できる状態に保つためには、業界の提携関係とパシフィック・エンデバーのようなワークショップを活用する以外に方法がありません。」

この国際イベントは軍事組織と国際的民間組織の間で提携関係を築き、人道支援や災害復旧活動に伴う通信業務を改善することに貢献するものです。パシフィック・エンデバーのワークショップは、シンガポールのチャンギ海軍基地で8月6〜10日に実施されます。

今年のイベントは、特に衛星通信を焦点とするもので、グローバルVSATフォーラム（GVF）がワークショップとして実地的な研修を2日間にわたって主導し、超小型地球局（VSAT）の設置・保守に関して受講者の資格認定を行ったりします。認定を取得した受講者は、公開のGVF設置者データベースに登録する選択肢を与えられます。

インテルサットとGVFは、アジア太平洋地域の受講者21〜25人を対象にした本研修コースの費用を分担し、GVFはその費用を同フォーラムのアンドリュー・ワース奨学金から拠出します。インテルサットは衛星「インテルサット22」の帯域幅を提供し、受講者が干渉を生じさせることなくアンテナを正しく設置する能力を実証できるように支援します。

インテルサットのアジア太平洋販売担当地域副社長を務めるテリー・ブリークリーは、次のように語っています。「衛星通信はグローバルな事業運営のほか、人道的活動や災害復旧活動においてますます重要なリソースになっています。現在、軌道上にある衛星と地上局の数は過去最多で、無線周波数環境は厳しい状況にあります。世界中のユーザーすべてが信頼できる通信サービスを確実に利用できる状態に保つためには、業界の提携関係とパシフィック・エンデバーのようなワークショップを活用する以外に方法がありません。」

GVFについて

GVFは世界の衛星業界にとって唯一の統一的な代表組織です。1997年に設立され、先進的な広帯域・狭帯域衛星サービスを世界の消費者や営利企業・国営企業に提供する諸組織を結び付けています。ロンドンに本拠を構えるGVFは、独立した無党派の非営利団体で、230を超える会員組織が100カ国以上から参加しています。その広範な会員層は世界の全主要地域と衛星業界の全セクターを網羅し、これらセクターには固定衛星・移動衛星事業者、衛星ネットワーク事業者、テレポート、衛星地上局メーカー、システムインテグレーター、付加価値サービスプロバイダー、拡張サービスプロバイダー、電気通信事業者、コンサルタント、法律事務所、ユーザーが含まれます。お問い合わせは英国オフィスの martin.jarrold@gvf.org 、または米国オフィスの david.hartshorn@gvf.org もしくは liz.grimm@gvf.org までご連絡ください。

インテルサットについて

インテルサットは衛星サービスの世界最大手です。インテルサットは45年以上にわたり、世界をリードする多数のメディア・ネットワーク企業、多国籍企業、インターネット・サービス・プロバイダー、政府機関に、情報とエンターテインメントを提供してきました。インテルサットの衛星、テレポート、光ファイバーのインフラストラクチャーは業界で群を抜いており、映像・データ・音声の伝送サービスで新たな標準を確立しています。コンテンツのグローバル化やHDの普及からセルラーネットワークやブロードバンドの拡大まで、インテルサットのサービスは高度な通信を世界のあらゆる場所で身近なものにしています。

インテルサットのセーフハーバー表明

本プレスリリースの記述には、過去の事実に直接的に関連していない記述として、または過去の事実に専ら関連しているのではない記述として、将来見通しに関する記述が一部に含まれています。本リリースの将来見通しに関する記述は、インテルサットの将来の出来事に関する意図、計画、予想、想定、考えに基づいており、リスク、不確実性やその他の要因の影響が伴い、そのほとんどにインテルサットの管理が及びません。既知のリスクとして、2011年12月31日締めの年度においてインテルサットがフォーム10-Kで提出した年次報告書や当社が米証券取引委員会に提出した書類に含まれるリスク、当社の通信サービスが対象とする市場もしくは当社が業務を行う市場の政治的・経済的・法的環境、電気通信事業一般、特に衛星通信業界に内在するその他のリスクや不確実性などがあります。実際の結果は、インテルサットの将来の出来事に関する意図、計画、予想、想定、考えと著しく異なる可能性があるため、本リリースに含まれるすべての将来見通しに関する記述は慎重に検討されるようご注意ください。インテルサットは新たな情報、将来の出来事、あるいはその他の理由の結果として、将来見通しに関する記述を更新・修正する義務を一切負いません。

本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。

「顧客基盤に近い立場に立つことが当社にとって重要です。新たなCGPは今後もノースカロライナで活動するため、当社はこの地域をサポートする上で理想的な立場にあります。同社事業のRFID部門では、中国華南の東莞にある当社工場内のRFID製造・革新デザインセンターと同様の業務を行います。また、CGPが蓄積しているRFIDの相当の技術的経験によって、SMLは西半球と東半球においてRFIDのViziT事業やソリューションを幅広く提供することができます。」

1988年創業のCGPは、製品革新をくまなく実施するとともに、包括的な製造センターを運営することで、感圧ラベル、品質表示タグ、折り畳み式ダンボール箱、見出しカード、冊子ラベル、クーポンラベルなど、フレキソ印刷およびオフセット印刷の両形式であらゆるブランド識別ラベルを製造してきました。2004年以来、CGPはRFIDラベルへの全面的な事業転換や電子製品コード（EPC）エンコード事業により、RFID事業で顕著な成長を記録しています。

SMLグループのグローバルRFID担当バイスプレジデントを務めるフィリップ・カルダーバンクは、次のように述べています。「顧客基盤に近い立場に立つことが当社にとって重要です。新たなCGPは今後もノースカロライナで活動するため、当社はこの地域をサポートする上で理想的な立場にあります。同社事業のRFID部門では、中国華南の東莞にある当社工場内のRFID製造・革新デザインセンターと同様の業務を行います。また、CGPが蓄積しているRFIDの相当の技術的経験によって、SMLは西半球と東半球においてRFIDのViziT事業やソリューションを幅広く提供することができます。」

CGP創業者のトミー・デュー氏が今後は新たなCGPでプレジデントの職を担い、同社はCGPの社名で事業を継続します。デュー氏は、次のように述べています。「事業拡大を続ける中で、当社の顧客から当社が世界各地で完成ラベルに印刷し、RFIDエンコードを施すことができるかについて、質問されるようになりました。世界的企業と合併しなければ、成長を続けることができないと分かったのです。SMLという企業を知ったこと、今後は同グループの世界各地の施設を活用して、中国から欧州や米国までの顧客に製品やサービスを提供できることを非常に喜んでいます。」

SMLグループのサイモン・スエン会長は、買収に関して次のように述べています。「SMLは卓越したブランド化ラベルの供給企業の1つとして、ViziTのブランド名で当社のRFID事業や製造施設の大規模な拡大に着手しました。世界中の小売り事業の顧客やそのサプライヤーに対して“調達先から店舗まで”の完全な可視性を提供することが、当社の目的です。CGPの買収は、当社の成長において新たな節目となる成果です。」

SMLグループについて

SMLは総合的なブランド識別ソリューションの世界的企業として、世界のトップファッションブランドや大手小売業者から成る国際的な顧客層にサービスを提供しています。当社の広範な高品質製品には、織ラベル、プリント布ラベル、電子式商品監視（EAS）システム、無線識別（RFID）、熱伝達製品、パッケージング、特殊トリム、印刷紙製品などがあります。30カ国を超える国々で事業を展開し、世界各地に完全所有の製造施設を構えており、万全の体制で世界中のお客様のニーズに効果的かつ効率的にお応えするとともに、品質・価格・サービス・スピードにおいて期待を上回るような取り組みを行っています。

SMLのViziTブランドでは、EASによる損失防止機能でRFID製品に可視性を付与しており、RFID対応のラベル・チケット・品質表示タグに加え、EPCシリアル番号によるチップエンコードのサービスを、世界規模でネットワーク化したサービス拠点を通じて提供しています。クラウドベースのITデータ管理ソリューションにより、ViziTパッケージを完璧なものとしています。

本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。

Highlights

• NYSE Euronext global derivatives ADV in July 2012 of 7.0 million contracts decreased 12.0% compared to July 2011 and decreased 15.8% from June 2012 levels.
• NYSE Euronext European derivatives products ADV in July 2012 of 3.5 million contracts decreased 6.8% compared to July 2011 and decreased 24.7% from June 2012. Excluding Bclear, NYSE Liffe's trade administration and clearing service for OTC products, European derivatives products ADV decreased 9.9% compared to July 2011 and decreased 8.5% from June 2012 levels.
• NYSE Euronext U.S. equity options ADV of 3.5 million contracts in July 2012 decreased 15.8% compared to July 2011 levels and decreased 3.8% from June 2012. NYSE Euronext’s U.S. options exchanges accounted for 25.9% of total U.S. consolidated equity options trading in July 2012, up from 25.8% in July 2011 and up from 25.6% in June 2012.
• NYSE Liffe U.S. ADV of approximately 53,400 contracts decreased from 101,300 contracts in July 2011 and decreased from 90,900 contracts in June 2012.
• NYSE Euronext European cash products ADV of 1.5 million transactions in July 2012 decreased 10.8% compared to July 2011 and decreased 12.3% from June 2012 levels.
• NYSE Euronext U.S. cash products handled ADV of 1.7 billion shares in July 2012 decreased 16.9% compared to July 2011 and decreased 9.9% compared to June 2012. NYSE Euronext’s Tape A matched market share in July 2012 was 32.1%, down from 34.3% in July 2011 and down from 32.3% in June 2012.

Derivatives Trading

European Derivatives

• NYSE Euronext European derivatives products ADV in July 2012 of 3.5 million contracts decreased 6.8% compared to July 2011 and decreased 24.7% from June 2012 levels.
• The 3.5 million in European derivatives futures and options contracts ADV in July 2012 consisted of 2.7 million contracts executed through our full-service LIFFE CONNECT trading platform and 0.8 million contracts, or 23.8%, executed through Bclear, NYSE Liffe's trade administration and clearing service for OTC products. Excluding Bclear, NYSE Liffe's trade administration and clearing service for OTC products, European derivatives products ADV decreased 9.9% compared to July 2011 and decreased 8.5% compared to June 2012.
• Year-to-date, European derivatives products ADV of 3.9 million contracts was 18.3% below prior year levels. The 3.9 million in futures and options contracts ADV year-to-date consisted of 2.8 million contracts executed through LIFFE CONNECT trading platform and 1.1 million contracts, or 29.3%, executed through Bclear.
• Total fixed income products ADV of 1.8 million contracts in July 2012 decreased 4.2% from July 2011 and decreased 6.4% from June 2012. Year-to-date, total fixed income products ADV of 1.9 million contracts was 21.1% below prior year levels.
• Total equity products (including Bclear) ADV of 1.5 million contracts in July 2012 decreased 12.1% compared to July 2011 and decreased 40.6% from June 2012. The 1.5 million contracts in equity products ADV in July 2012 consisted of 1.1 million contracts in individual equity products ADV and 0.4 million contracts in equity index products ADV. The 1.1 million contracts in individual equity products ADV consisted of 0.7 million in futures contracts, which represented a 4.0% increase compared to July 2011 and 0.4 million in options contracts, which represented a 21.5% decrease compared to July 2011. The average net rate per contract for individual equity futures contracts is significantly lower than other European derivatives products. Year-to-date, total equity products ADV of 2.0 million contracts was 16.3% below prior year levels.
• Total commodities products ADV of approximately 119,000 contracts in July 2012 increased 52.2% compared to July 2011 and increased 45.5% compared to June 2012. Year-to-date, total commodities product ADV of 86,000 contracts was 0.7% above prior year levels.

U.S. Derivatives

• NYSE Euronext U.S. equity options ADV of 3.5 million contracts in July 2012 decreased 15.8% compared to July 2011 and decreased 3.8% compared to June 2012. Year-to-date, U.S. equity options ADV of 3.9 million contracts was 6.5% below prior year levels.
• Total U.S. consolidated equity options ADV decreased 16.1% to 13.5 million contracts in July 2012 compared to July 2011 and decreased 5.1% compared to June 2012. Year-to-date, U.S. consolidated equity options ADV of 15.1 million contracts was 8.2% below prior year levels.
• NYSE Euronext’s U.S. options exchanges accounted for 25.9% of total U.S. consolidated equity options trading in July 2012, up from 25.8% in July 2011 and up from 25.6% in June 2012.
• NYSE Liffe U.S. ADV of approximately 53,400 contracts decreased from 101,300 contracts in July 2011 and decreased from 90,900 contracts in June 2012. Year-to-date, U.S. futures and futures options ADV of 80,200 contracts was 26.4% above prior year levels.

Cash Trading

European Cash

• NYSE Euronext European cash products ADV of 1.5 million transactions in July 2012 decreased 10.8% compared to July 2011 and decreased 12.3% compared to June 2012.
• Year-to-date, European cash products ADV of 1.6 million transactions was 3.0% below prior year levels.

U.S. Cash

• NYSE Euronext U.S. cash products handled ADV in July 2012 decreased 16.9% to 1.7 billion shares compared to July 2011 and decreased 9.9% from June 2012.
• Year-to-date, U.S. cash products handled ADV was 1.8 billion shares, down 17.8% from prior year levels.
• NYSE Euronext’s Tape A matched market share in July 2012 was 32.1%, down from 34.3% in July 2011 and down from 32.3% in June 2012.

Exchange Traded Funds

• NYSE Euronext U.S. matched exchange-traded funds ADV (included in volumes for Tape B and Tape C) of 195 million shares in July 2012 decreased 29.7% compared to July 2011 and decreased 20.5% compared to June 2012.
• Year-to-date, NYSE Euronext U.S. matched exchange-traded funds ADV of 225 million shares was 19.7% below prior year levels.

Please click here for the Monthly Transaction Activity Data Table.

About NYSE Euronext

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets - the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca - represent one-third of the world’s equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: http://www.nyx.com.

Disclaimer and Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning NYSE Euronext's plans, objectives, expectations and intentions and other statements that are not historical or current facts. Forward-looking statements are based on NYSE Euronext's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause NYSE Euronext's results to differ materially from current expectations include, but are not limited to: NYSE Euronext's ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk and U.S. and global competition, and other factors detailed in NYSE Euronext's 2011 Annual Report on Form 10-K and other periodic reports filed with the U.S. Securities and Exchange Commission or the French Autorité des Marchés Financiers. In addition, these statements are based on a number of assumptions that are subject to change. Accordingly, actual results may be materially higher or lower than those projected. The inclusion of such projections herein should not be regarded as a representation by NYSE Euronext that the projections will prove to be correct. This press release speaks only as of this date. NYSE Euronext disclaims any duty to update the information herein.

„Dies ist nun für alle ein günstiger Zeitpunkt, um ihre Wahrnehmung von Qt zu überdenken. Mit seinen zielgerichteten Investitionen in Forschung und Entwicklung wird Digia Qt für Desktops und eingebettete Plattformen wieder in den Vordergrund rücken und auch seine Unterstützung mobiler Betriebssysteme ausweiten.“

Eines der Hauptziele, die Digia mit dieser Übernahme verfolgt, ist die Verbesserung seiner Position innerhalb des Qt-Ökosystems, indem es die Forschungs- und Entwicklungskapazitäten von Qt weiter ausbaut und seine Reichweite auf deutlich mehr Plattformen als je zuvor ausdehnt. Seit Digia das Geschäft mit kommerziellen Qt-Lizenzen im März 2011 von Nokia kaufte, war dieses weiterhin erfolgreich und ist bedeutend gewachsen. Den Prognosen von Digia zufolge wird sich die Übernahme positiv auf seine Umsätze des Jahres 2012 auswirken. Digia erwartet, dass das Qt-Geschäft in den folgenden Jahren wachsen wird. Im Rahmen der Transaktion werden bis zu 125 Qt-Mitarbeiter von Nokia zu Digia wechseln. Die meisten davon arbeiten an den Niederlassungen in Oslo, Norwegen, und Berlin, Deutschland. Diese Transaktion wird das Produktgeschäft von Digia deutlich verstärken und seine strategische Zielsetzung von internationalem Wachstum unterstützen.

Digia ermutigt alle derzeitigen Mitglieder des Ökosystems, ihre Arbeit an der Verbesserung von Qt mit der uneingeschränkten Gewissheit fortzusetzen, dass Digia weiter investieren wird, um Qt zum führenden Rahmensystem für die plattformübergreifende Entwicklung zu machen. Digia wird mit den Mitgliedern des Ökosystems zusammenarbeiten, um den erfolgreichen Auftritt von Qt5 zu gewährleisten. Das Unternehmen ist entschlossen, das Qt-Projekt fortzuführen, um die Verfügbarkeit von Qt unter sowohl Open-Source- als auch kommerziellen Lizenzen aufrechtzuerhalten.

„Wir freuen uns darauf, das Qt-Team bei Digia willkommen zu heißen. Indem wir diese erstklassige Organisation zu unserem bestehenden Team hinzufügen, wollen wir die führende Umgebung der nächsten Generation für die plattformübergreifende Softwareentwicklung schaffen“, sagte Tommi Laitinen, SVP, International Products, Digia. „Dies ist nun für alle ein günstiger Zeitpunkt, um ihre Wahrnehmung von Qt zu überdenken. Mit seinen zielgerichteten Investitionen in Forschung und Entwicklung wird Digia Qt für Desktops und eingebettete Plattformen wieder in den Vordergrund rücken und auch seine Unterstützung mobiler Betriebssysteme ausweiten.“

„Nokia ist stolz auf die Beiträge, die wir während der vergangenen vier Jahre zur Entwicklung von Qt geleistet haben. Wir freuen uns, dass wir mit Digia zusammenarbeiten konnten, um die fortgesetzte Entwicklung von Qt durch das gegenwärtige Kernteam zu sichern“, erklärte Sebastian Nyström, Leiter von Nokia Strategy. „Digias Übernahmepläne für Qt bedeuten, dass es als ein erfolgreiches Open-Source-Projekt fortbestehen kann, aber auch vielen Menschen innerhalb der Gemeinde weiterhin Arbeitsplätze bietet.“

Qt wurde von mehr als 450.000 Entwicklern und tausenden der führenden Unternehmen aus aller Welt in über 70 Branchen als Grundlage für die innovativsten, erfolgsentscheidendsten und berühmtesten Anwendungen und Nutzeroberflächen eingesetzt. Qt Commercial ist ein Marktführer in einer Reihe wichtiger Segmente, darunter Kfz, medizinische Geräte, fortgeschrittene Visualisierung und Animation, industrielle Automatisierung sowie Aerospace und Verteidigung. Digia erwartet, dass Qt in Zukunft eine Schlüsselrolle spielen wird, wenn es darum geht, erstklassige Nutzererfahrungen und Bedienoberflächen auf eingebettete Systeme und elektronische Unterhaltungsgeräte zu bringen.

Weitere Informationen werden in Kürze unter qt.digia.com und qt-project.org erhältlich sein, den beiden Hauptinformationsportalen für Qt.

ÜBER DIGIA

Digia ist ein Software- und Serviceunternehmen mit Sitz in Finnland. Es beschäftigt nahezu 1000 Fachkräfte, die innovative Lösungen schaffen und Menschen, Unternehmen und Gemeinden im alltäglichen leben zum Erfolg verhelfen. Wir verbessern die Wettbewerbsfähigkeit unserer Kunden mit kanalübergreifenden Unternehmenslösungen, welche die Effektivität und die Kundenerfahrung verbessern. Unsere Kunden vertrauen auf unsere kenntnisreichen Spezialisten, unser tiefgreifendes Branchenverständnis und die breitgefächerten Kompetenzen, für die wir bekannt sind. Unsere innovativen Produkte sind für Menschen in aller Welt erreichbar.

Wir liefern ICT-Lösungen und Dienstleistungen an verschiedene Branchen, mit besonderem Fokus auf das Finanzwesen, den öffentlichen Sektor, das Handels- und Dienstleistungsgewerbe sowie die Telekommunikation. Digia ist in Finnland, Russland, China, Schweden, Norwegen und den USA aktiv. Das Unternehmen ist an der NASDAQ OMX Helsinki notiert (DIG1V).

Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.

«Nokia est fière des contributions que nous avons faites pour Qt au cours des quatre dernières années. Nous sommes heureux d'avoir pu travailler avec Digia pour assurer un développement continu de Qt par l'équipe principale actuelle»

L'un des principaux objectifs de Digia avec cette acquisition consiste à améliorer sa position au sein de l'écosystème de Qt en renforçant davantage les capacités de R et D de Qt et en étendant sa portée sur beaucoup plus de plate-formes que jamais auparavant. Depuis que Digia a acquis l'activité d'octroi de licences commerciales de Qt auprès de Nokia en mars 2011, l'activité a poursuivi sa réussite et elle s'est considérablement développée. Digia prévoit un impact positif de l'acquisition sur ses revenus pour 2012. Au cours des années suivantes, Digia prévoit une croissance des activités de Qt. Dans le cadre de la transaction, jusqu'à 125 employés de Qt auprès de Nokia seront affectés chez Digia, dont la plupart sont basés à Oslo en Norvège et à Berlin en Allemagne. Cette transaction commerciale renforcera considérablement les lignes de produits de Digia et soutiendra l'objectif stratégique de Digia en termes de croissance internationale.

Digia encourage tous les membres actuels de l'écosystème à poursuivre leur travail dans l'amélioration de Qt avec une confiance totale dans les investissements continus de Digia pour faire de Qt le chef de file du cadre de développement multiplate-forme. Digia travaillera avec les membres de l'écosystème pour assurer la réussite du lancement de Qt5 et elle est engagée dans la poursuite du projet Qt afin de maintenir la disponibilité de Qt en licences ouvertes et commerciales.

« Nous nous réjouissons à la perspective d'accueillir l'équipe de Qt chez Digia. Avec l'ajout de cette entreprise de premier plan à notre équipe existante, nous envisageons de créer un environnement de développement multiplate-forme leader de nouvelle génération, » a déclaré Tommi Laitinen, Vice-président directeur des produits internationaux chez Digia. « Le moment est venu pour chacun de revisiter sa perception sur Qt. Les investissements en R et D ciblés de Digia ramèneront l'accent sur la prise en charge de bureau et de plate-forme intégrée de Qt tout en élargissant la prise en charge de systèmes d'exploitation mobiles. »

« Nokia est fière des contributions que nous avons faites pour Qt au cours des quatre dernières années. Nous sommes heureux d'avoir pu travailler avec Digia pour assurer un développement continu de Qt par l'équipe principale actuelle, » a indiqué Sebastian Nyström, responsable de la stratégie chez Nokia. « Le projet d'acquistion de Qt par Digia signifie que la réussite du projet Qt de sources libres se poursuivra et qu'il offrira également un emploi continu à beaucoup de personnes dans la communauté. »

Qt a été utilisée par plus de 450 000 développeurs et des milliers de sociétés majeures à travers le monde dans plus de 70 industries pour développer les applications et IU les plus innovantes, essentielles et réputées. Qt Commercial est un leader dans une multitude de segments de marché clés, notamment les secteurs de l'automobile, de la médecine, de la visualisation et animation avancées, de l'automatisation industrielle et de l'aérospatial et défense. Dans l'avenir, Digia prévoit que Qt jouera un rôle clé en orientant l'expérience et les interfaces d'utilisateurs de premier plan vers les systèmes intégrés et l'électronique grand public.

Plus d'informations seront bientôt disponibles sur qt.digia.com et qt-project.org, qui seront les principaux sites de partage d'informations pour Qt.

À PROPOS DE DIGIA

Digia est une société finlandaise de solutions logicielles et de services. Nous comptons près de 1 000 professionnels qui créent des solutions inventives et permettent aux gens, aux entreprises et aux communautés de réussir dans leur vie de tous les jours. Nous renforçons la compétitivité de nos clients par des solutions d'entreprise à multiples canaux qui améliorent l'efficacité et l'expérience des clients. Nos clients font confiance à nos spécialistes avisés, à notre compréhension approfondie de l'industrie et à notre vaste savoir-faire technologique reconnu. Nos produits innovants sont à la portée des gens de par le monde.

Nous fournissons des solutions et services de TIC à diverses industries, nous focalisant principalement sur la finance, le secteur public, le commerce et les services et télécommunications. Digia a des activités en Finlande, en Russie, en Chine, en Suède, en Norvège et aux États-Unis. La société est cotée à la bourse des valeurs NASDAQ OMX Helsinki (DIG1V).

Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.

“Nokia está orgullosa de las contribuciones que hemos hecho a Qt en el transcurso de los últimos cuatro años. Nos sentimos satisfechos de haber podido trabajar con Digia para asegurar el desarrollo continuo de Qt por parte del equipo básico actual”

Uno de los objetivos clave de Digia en esta adquisición es mejorar su posición dentro del ecosistema de Qt, fortaleciendo aún más la capacidad de I+D de Qt y expandiendo su llegada a muchas más plataformas que antes. Desde que Digia adquirió de Nokia el negocio de licencias de Qt Commercial en marzo de 2011, la operación mantuvo su enorme éxito y ha crecido considerablemente. Digia considera que la adquisición tendrá un impacto positivo sobre las ganancias del ejercicio 2012. Además, la empresa pronostica un crecimiento en los negocios de Qt para los próximos años. Como parte de la transacción, se transferirá un máximo de 125 empleados de Qt en Nokia a Digia, en su mayoría desde las sedes de Oslo, Noruega, y Berlín, Alemania. Esta transacción fortalecerá considerablemente los negocios de los productos de Digia y sustentará el objetivo estratégico de Digia de crecer en el plano internacional.

Digia alienta a los miembros actuales del ecosistema a que continúen trabajando para mejorar Qt, con la plena seguridad de que Digia seguirá invirtiendo para que Qt se convierta en el marco de desarrollo líder para diversas plataformas. Digia trabajará con miembros del ecosistema para asegurar un lanzamiento exitoso de Qt5, y se compromete a seguir avanzando con el Proyecto Qt para mantener la disponibilidad de Qt tanto bajo licencias de código abierto como comerciales.

"Estamos ansiosos por darle la bienvenida al equipo de Qt a Digia. Con la incorporación de esta organización de primera clase a nuestro equipo, planeamos construir el entorno de desarrollo líder para diversas plataformas de la próxima generación", aseguró Tommi Laitinen, vicepresidente ejecutivo de productos internacionales de Digia. "Este es un buen momento para que todos replanteen su percepción de Qt. Las inversiones centradas en I+D de Digia traerán de vuelta el foco al soporte de Qt para plataformas de equipos de escritorio y dispositivos integrados, aumentando al mismo tiempo el soporte para sistemas operativos móviles".

"Nokia está orgullosa de las contribuciones que hemos hecho a Qt en el transcurso de los últimos cuatro años. Nos sentimos satisfechos de haber podido trabajar con Digia para asegurar el desarrollo continuo de Qt por parte del equipo básico actual", señaló Sebastian Nyström, a cargo de Nokia Strategy. "Los planes de Digia de adquirir Qt implican la posibilidad de seguir siendo un proyecto exitoso de código abierto y además de ofrecer continuidad de empleo a mucha gente en la comunidad".

Qt ha sido usado por más de 450.000 desarrolladores y miles de compañías líderes de todo el mundo en más de 70 industrias para potenciar las aplicaciones y UI más innovadoras, esenciales y renombradas. Qt Commercial es líder en una serie de segmentos clave del mercado que incluyen a la industria automotriz, medicina, visualización y animación de avanzada, automatización industrial y la industria aeroespacial y de defensa. Digia considera que en el futuro, Qt será fundamental para prestar servicios de primer nivel y generar interfaces para el usuario en sistemas integrados y electrónica de consumo.

En breve se podrá consultar más información en qt.digia.com y qt-project.org, los principales canales para difundir la información de Qt.

ACERCA DE DIGIA

Digia es una compañía finlandesa de soluciones y servicios de software. Tenemos más de 1.000 profesionales generando soluciones creativas y contribuyendo al éxito cotidiano de las personas, los negocios y las comunidades. Mejoramos la competitividad de nuestros clientes con soluciones empresariales en múltiples canales que mejoran la efectividad y la calidad de los servicios para el cliente. Nuestros clientes confían en el conocimiento de nuestros especialistas, nuestra profunda comprensión de la industria y nuestra amplia y reconocida experiencia en tecnología. Nuestros productos son innovadores y están al alcance de la gente en todo el mundo.

Brindamos soluciones y servicios de tecnología de la información a varias industrias, especialmente en el sector de las finanzas, el sector público, el comercio y los servicios y las telecomunicaciones. Digia opera en Finlandia, Rusia, China, Suecia, Noruega y Estados Unidos. La compañía cotiza en la bolsa de Helsinki de NASDAQ OMX (DIG1V).

El texto original en el idioma fuente de este comunicado es la versión oficial autorizada. Las traducciones solo se suministran como adaptación y deben cotejarse con el texto en el idioma fuente, que es la única versión del texto que tendrá un efecto legal.

“We are looking forward to welcoming the Qt team to Digia. By adding this world class organization to our existing team we plan to build the next generation leading cross-platform development environment”

One of Digia’s key objectives with this acquisition is to improve its position within the Qt ecosystem by further strengthening Qt’s R&D capabilities and expanding its reach on many more platforms than ever before. Since Digia acquired the Qt Commercial licensing business from Nokia in March 2011, the operation has continued to be successful and has grown substantially. Digia forecasts the acquisition’s impact on its 2012 revenues to be positive. In the following years, Digia forecasts the Qt business to grow. As part of the transaction, a maximum of 125 Qt people from Nokia will transfer to Digia, mostly based in Oslo, Norway and Berlin, Germany. This business transaction will significantly strengthen Digia’s product business and supports Digia's strategic objective to grow internationally.

Digia encourages all current ecosystem members to continue working on improving Qt with full confidence in Digia’s continued investment to make Qt the leading cross-platform development framework. Digia will work with ecosystem members to secure a successful release of Qt5 and is committed to continuing the Qt Project in order to maintain Qt’s availability under both open source and commercial licenses.

“We are looking forward to welcoming the Qt team to Digia. By adding this world class organization to our existing team we plan to build the next generation leading cross-platform development environment,” said Tommi Laitinen, SVP, International Products, Digia. “Now is a good time for everyone to revisit their perception of Qt. Digia’s targeted R&D investments will bring back focus on Qt’s desktop and embedded platform support, while widening the support for mobile operating systems.”

"Nokia is proud of the contributions we've made to Qt over the past four years. We are pleased that we've been able to work with Digia to secure continued development of Qt by the current core team," said Sebastian Nyström, head of Nokia Strategy. "Digia's plans to acquire Qt mean that it can continue as a successful open source project and also offer continuing employment for many people in the community."

Qt has been used by over 450,000 developers and thousands of leading companies worldwide in over 70 industries to power the most innovative, mission-critical and renowned applications and UIs. Qt Commercial is a leader in a number key market segments including automotive, medical, advanced visualization & animation, industrial automation and aerospace & defense. In the future, Digia expects that Qt will have a key role bringing world-class user experience and user interfaces to embedded systems and consumer electronics.

More information will be available shortly on qt.digia.com and qt-project.org which will be the main information-sharing sites for Qt.

ABOUT DIGIA

Digia is a Finnish software solutions and service company. We have nearly 1,000 professionals creating inventive solutions and bringing success for people, businesses and communities in everyday life. We improve our customers’ competitiveness with multi channeled enterprise solutions that improve effectiveness and customer experience. Our customers trust our insightful specialists, our deep industry comprehension and recognized wide-ranging technology know-how. Our innovative products are within reach of people around the world.

We deliver ICT solutions and services to various industries, focusing especially on finance, public sector, trade and services and telecommunications. Digia operates in Finland, Russia, China, Sweden, Norway and in the U.S. The company is listed on the NASDAQ OMX Helsinki exchange (DIG1V).

Hexagon: (STO:HEXAB)

Second Quarter 2012

· Operating net sales increased by 12 per cent to 607.1 MEUR (543.5)

· Using fixed exchange rates and a comparable group structure, net sales increased by 6 per cent

· Operating earnings (EBIT1) amounted to 127.5 MEUR (114.3)

· Earnings before taxes, excluding non-recurring items, amounted to 114.7 MEUR (99.5)

· Net earnings increased by 22 per cent to 92.8 MEUR (76.3)

· Earnings per share increased by 18 per cent to 0.26 EUR (0.22)

· Operating cash flow increased by 175 per cent to 71.5 MEUR (26.0)

The interim report for the second quarter 2012 will be presented today at 15:00 CET at a telephone conference. For participation, please see instructions on the Hexagon website.

Hexagon is a leading global provider of design, measurement and visualisation technologies. Our customers can design, measure and position objects, and process and present data, to stay one step ahead of a changing world. Hexagon’s solutions increase productivity, enhance quality and allow for faster, better operational decisions, saving time, money and resources. Hexagon has over 13 000 employees in more than 40 countries and net sales of about 2 200 MEUR. Our products are used in a broad range of industries including surveying, power and energy, aerospace and defence, safety and security, construction and manufacturing. Learn more at www.hexagon.com.

This information was brought to you by Cision http://www.cisionwire.com

• The Board of Directors of Precise Biometrics (“Precise Biometrics”) (STO:PREC) has resolved, subject to approval of the EGM on September 11, 2012, to undertake a rights issue with preferential rights for Precise Biometrics’ shareholders of approximately SEK 55 million.
• The rights issue is implemented to finance increased working capital due to new orders, develop Tactivo ™ and to ensure a more cost-effective alternative to the current credit facility.
• The rights issue is guaranteed up to a level of 70% of the rights issue, approximately SEK 38,5 million.
• The terms and conditions for the rights issue, including the subscription price and ratio basis, will be established and announced on September 7, 2012.
• Following approval of the EGM, the subscription period will run from September 19, 2012 until October 3, 2012.

”The newly developed product line Tactivo™ is the world's first product for smartphones with built-in smart card reader and fingerprint sensor. Tactivo™ has received a positive response and we expect that the products will account for the majority of our sales already this year, but are especially crucial to Precise Biometrics' growth and profitability for years to come. Based on independent information from the Gartner Group and our own assessments, we believe that there is a significant potential for Precise Biometrics at about four million units in 2015.

These opportunities in the mobile market also form the background for Precise Biometrics current rights issue. We need good finances to carry out our global market launch and develop production in line with our growth plans. We need to continue to develop our organization, building our network of contacts and establish new capabilities in the U.S., where the potential for new products is significant.” says Thomas Marschall, CEO at Precise Biometrics.

Background and rationale

Precise Biometrics has in 2012 launched Tactivo™ - the world's first product for smartphones with built-in fingerprint and smart card readers for the iPhone. Tactivo™ provides a high level of mobile security for users wishing to access information or cloud-based services through their smartphones, but which are prevented for security reasons or lack of user friendliness. By replacing passwords with your ID card or a fingerprint Tactivo™ solves the problems and risks that currently exist with mobile devices. This is particularly important for government, healthcare and banks.

The launch of Tactivo™ is expected to provide a significant positive impact on the Company's sales and profitability by expanding Precise Biometrics' technology to a new market, as evidenced by the orders received from one of the world's largest vehicle manufacturers in June 2012 and the first orders and pilot projects for the U.S. Federal authorities announced in August 2012. As a result, Precise Biometrics is experiencing a massive interest in Tactivo™. A part of the issue proceeds will be used to finance new orders through increased working capital in the form of build-up of inventories and the costs associated with launching and development of Tactivo™, such as product development other brands of smartphones and tablets. Further, rights issue proceeds will ensure a more cost effective alternative to the current credit facility, announced in March 2012.

Terms and conditions for the rights issue

The Board of Directors of Precise Biometrics has resolved to, subject to approval of the EGM on September 11, to undertake a rights issue of maximum SEK 55 million with preferential rights for current shareholders. Current shareholders have preferential right to subscribe new shares in relation to shares held at the record day September 17, 2012. The subscription period runs from September 19, 2012 until October 3, 2012, following approval of the EGM on September 11, 2012.

Shares that are not subscribed for on basis of subscription rights should primarily be allocated to those who have subscribed for shares on basis of subscription rights, pro rata in relation to their subscription on the basis of subscription rights, secondarily to those who have declared their interest to subscribe for shares without subscription rights, pro rata in relation to their declared interest and thirdly, as agreed, to guarantors.

Guarantees

Precise Biometrics has received guarantees from external investors to subscribe for additional shares to secure that the rights issue is subscribed up to a subscription level of at least 70%, approximately an amount of SEK 38,5 million. The guarantors have agreed to subscribe for the difference between 70% of the rights issue and the amount subscribed (with and without subscription rights).

Preliminary timetable for the rights issue

The subscription price and ratio basis will be determined on September 7, 2012 Extra ordinary general meeting in Precise Biometrics September 11, 2012 Prospectus is published September 11, 2012 Last day of trading in the share with right to participate in the new issue September 12, 2012 First day of trading in the share without right to participate in the new issue September 13, 2012 Record day for participation in the new issue of shares September 17, 2012 Subscription period for the rights issue September 19 – October 3, 2012 Trading in subscription rights September 19 – 28, 2012 Trading in paid subscribed shares September 19, 2012 until the share issue is registered at the Swedish Companies Registration Office The notice to the EGM and prospectus including detailed terms on the rights issue will be published separately.

Financial advisor

Remium Nordic AB is acting as financial adviser to Precise Biometrics in conjunction with the rights issue.

Important information

The publication or distribution of this press release may in certain jurisdictions be subject to restriction by law, and persons in the jurisdictions where this press release has been published or distributed should inform themselves of and follow such legal restrictions.

This press release may not be made public, published or distributed, either directly or indirectly in the United States, Canada, Japan, New Zealand, South Africa, Australia or any other country where such procedures are subject in full or in part to legal restrictions. Nor may the information in this press release may not be communicated, reproduced or presented in any way that is in conflict with such restrictions. Failure to follow this instruction may involve a breach of the United States Securities Act from 1933 ("Securities Act") or applicable laws in other jurisdictions.

In any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”) other than Sweden, Denmark and the United Kingdom, this press release is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive (or are other persons to whom a public offering of securities may lawfully be addressed under the Prospectus Directive).

This press release does not contain or constitute an invitation or offer to acquire, subscribe to or otherwise trade with shares, subscription rights or other securities in Precise Biometrics. The invitation to the persons concerned to subscribe to shares in Precise Biometrics will only take place through the Prospectus that Precise Biometrics intends to publish, and this Prospectus will contain financial statements and other information on Precise Biometrics’ board of directors and auditors.

Neither the subscription rights, paid subscribed shares or the new shares will be registered in accordance with the Securities Act or any other act in Canada, and may not be transferred or offered for sale in the United States or Canada, or to persons domiciled there, or on behalf of such persons, other than in such exceptional cases where registering in accordance with the Securities Act or other act in Canada is not required.

This press release may contain forward-looking statements. When used in this press release, words such as “evaluate”, “expect” and “intend” are intended to identify forward-looking statements. They may involve risks and uncertainties, including product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of the management as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by the management and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Precise Biometrics disclaims any intention or obligation to update these forward-looking statements.

Precise Biometrics AB (publ) may be required to disclose the information provided herein pursuant to the Securities Markets Act. The information was submitted for publication at 08.00 on August 9, 2012.

Precise Biometrics is a market-leading provider of solutions for fingerprint recognition to prove people's identities. With top-of-the-line expertise in fingerprint verification, Precise Biometrics offers fast, accurate and secure authentication of a person.

The technology adds value to ID, enterprise and bank cards as well as access to mobile solutions, computers and networks. Precise Biometrics serves business and government organizations throughout the world and its technology is licensed to close to 160 million users.

For more information, please visit www.precisebiometrics.com

This information was brought to you by Cision http://www.cisionwire.com

Second quarter

• Rental revenue SEK 6.6 M (6.9)
• Operating profit SEK 3.8 M (1.5)
• Profit before tax SEK 1.4 M (0.8)
• Unrealized changes in property value SEK -0.5 M (1.3)
• Investments in continuing operations SEK 0.5 M (1.3)
• Profit after tax SEK 1.1 M (-0.3)
• Rental revenue SEK 13.3 M (13.8)
• Operating profit SEK 22.6 M (31.5)
• Profit before tax SEK 17.9 M (32.6)
• Unrealized changes in property value SEK 14.3 M (30.3)
• Investments in continuing operations SEK 0.7 M (1.7)
• Profit after tax SEK 13.3 M (90.7)

The period January-June

• Rental revenue SEK 13.3 M (13.8)
• Operating profit SEK 22.6 M (31.5)
• Profit before tax SEK 17.9 M (32.6)
• Unrealized changes in property value SEK 14.3 M (30.3)
• Investments in continuing operations SEK 0.7 M (1.7)
• Profit after tax SEK 13.3 M (90.7)

CEO Andreas Philipson comments

In the second quarter, we continued to focus on completing the zoning plan and development contract for Haga Norra. Accordingly, this work involves no major changes since the beginning of the year. The zoning plan was exhibited ahead of the summer, and its definitive approval by the City of Solna is expected in the fall. This process is a key component for us being able to realize the future Haga Norra, with new housing and workplaces.

The response has been positive in the ongoing letting work to find tenants for the site. We also believe strongly that Haga Norra is attractive. It is centrally located in the new Solna-Stockholm district, which is an up-and-coming area between Hagastaden, Frösunda, the Mall of Scandinavia and the National Arena.

We also strengthened our organization, appointing Lars Lindvall as our new CFO. Lars’ previous positions include being an accounting and corporate consultant, as well as holding executive positions in the Norsk Hydro group.

Otherwise, operating activities progressed as planned, with continued stable cash flow from tenants. Profit before tax was SEK 17.9 M, compared to SEK 32.6 M in the corresponding period of the previous year. The difference is mainly in a lower value increase on properties. We have unchanged property values compared to the first quarter. Compared to a year ago, the difference is an increase of SEK 73 M.

N.B. This is a translation from Swedish. The Swedish version shall always take precedence. This information is such that Catena AB (publ) must release it publicly in accordance with the Swedish Securities and Clearing Operations Act and/or the Financial Instruments Trading Act. The information was released to the public on August 9, 2012, at 08.00 a.m.

Catena shall own, effectively manage and actively develop well situated real estate with the potential to generate steadily growing cash flow and healthy value growth. Catena’s overriding objective, based on its focused orientation, is to provide shareholders with a favourable, long-term total return. For more information about Catena, visit www.catenafastigheter.se (http://www.catenafastigheter.se/)

This information was brought to you by Cision http://www.cisionwire.com

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

(b) Rights to subscribe for new securities (including directors’ and other executive options)

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

(a) Purchases and sales

(b) Derivatives transactions (other than options)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

(ii) Exercising

(d) Other dealings (including subscribing for new securities)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

(b) Agreements, arrangements or understandings relating to options or derivatives

(c) Attachments

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

The Current Report on Form 8-K, as filed with the U.S. Securities and Exchange Commission (SEC) on 24 July 2012, may be viewed on the SEC website at www.sec.gov and on the Virgin Media website at www.virginmedia.com/investors.

Virgin Media Inc.
Investor Relations:
Richard Williams, +44 (0)1256 753037
richard.williams@virginmedia.co.uk
or
Vani Bassi, +44 (0)1256 752347
vani.bassi@virginmedia.co.uk
or
Media:
At Virgin Media
Gareth Mead, +44 (0) 20 7299 5703
gareth.mead@virginmedia.co.uk
or
At Tavistock Communications
Matt Ridsdale, +44 (0) 20 7920 3150
mridsdale@tavistock.co.uk

The Current Report on Form 8-K, as filed with the U.S. Securities and Exchange Commission (SEC) on 24 July 2012, may be viewed on the SEC website at www.sec.gov and on the Virgin Media website at www.virginmedia.com/investors.

Chapel Down Group Plc
(`CDG' or `the Company')
EPIC: CDG

UNAUDITED RESULTS FOR THE SIX MONTHS ENDED 30^th JUNE 2012

Chapel Down Group PLC is pleased to announce the Company’s Interim Results for the six month period ended 30 June 2012.

SUMMARY

• Intense and favourable media coverage has continued to help us build awareness and create a premium brand positioned for sustainable future growth.
• Recent awards include a coveted Gold Medal for Chapel Down Rose Brut at the International Wine Challenge 2011, The Gore-Brown Trophy for the best English wine 2012 for Bacchus Reserve 2010 and our Curious Brew beer won Gold at the International Beer Challenge 2012.
• We have worked with the official Olympic suppliers of wine – Bibendum – to supply Chapel Down over the Olympic Games period to Olympic and other venues including Spencer House and City Hall.
• We continue to develop the highest quality listings for our wines and high profile restaurants including Harvey Nichols and The Royal Opera House.
• Turnover up 34% at £2,151,039 (2011: £1,609,932) due to a 19% increase in the volume of wine sold combined with a 6% increase in average selling price (excluding duty and VAT). The “Curious” range of beers saw a 234% increase in turnover against the same period last year.
• Gross profit up 23% at £871,605 (2011: £708,375). Gross profit margin was 41% compared to 44% in the comparative period reflecting the impact of the closure of the restaurant in the first half of the year. The restaurant has reopened as the “Swan at Chapel Down” and will make a positive contribution in the second half of the year.
• Operating profit up 39% at £155,055 compared with an operating profit of £111,753 in the same period last year.
• Pre-tax profit up 106% at £79,982 compared with a profit of £38,851 in the comparative period excluding the effect of the FRS20 share option provisions (note 2).
• Average selling price (excluding duty and VAT) is 6% above prior year.

CHAIRMAN’S STATEMENT

In an extremely challenging trading environment, with intense competitive activity, your Company continues to thrive. We have attracted important new customers, retained all our critical accounts and listings, significantly improved our trading performance and are continuing to build the Chapel Down brand into a very valuable asset. English wines are firmly in the ascendancy and Chapel Down is at the vanguard.

We have continued to improve the brand experience at our retail and tourism facility at Tenterden and our new partners, the Swan are proving to be outstanding at delivering great value and great food. If you have not visited our facility at Tenterden before, then I would urge you to do so to experience the professionalism and passion that is driving the industry forwards. The benefits to shareholders have been improved and we offer great discounts on wine, beer, food, tours and gifts.

In the six months to June 2012, the Group made a pre-tax profit of £79,982 compared to £38,851 in the 6 months to June 2011, an increase of 106%.*

Turnover increased by 34% to £2.15m with a gross profit of £0.87m (a 41% gross profit margin). It has been a constant theme in my statements to say that demand for our wines exceeds our ability to supply and in 2012 this has been even more so. It is our mission to ensure that this remains the case even as we increase supply and we will continue to invest in our brand to ensure our continued success.

Discussions continue with existing and new growers to increase their acreage of vines to fuel future sales of high quality, high margin wines, whilst over the coming years we await the shake out of new entrants who have planted speculatively.

Further awards, along with the extensive and very positive press coverage continued to build our reputation for high quality and professionalism.

We are unashamedly a brand-led business and we aim to build Chapel Down into a very valuable asset. We partner with some of England’s great chefs, including Gordon Ramsay, Gary Rhodes and Jamie Oliver as well as some of the UK’s leading retailers such as Majestic, Morrison’s, Marks and Spencer, Waitrose and Selfridges to ensure the brand is in the right places to sell and be seen. Indeed, we are proud and excited to be sole wine and beer suppliers to Jamie Oliver’s exciting new Union Jacks restaurants concept. We worked with the official Olympic suppliers of wine – Bibendum – to supply Chapel Down over the Olympic period to Olympic and other venues. We have also been exporting our wines to UAE, Japan, Finland, Hong Kong and France.

Curious Brew beer won The International Beer Challenge Gold Medal in 2012 – an outstanding achievement for such a young brand. As a result, demand for the beer is rising even more rapidly and we are already on trial in Mitchell and Butler pubs as well as a number of highly prestigious bars and restaurants across the South East.

The undoubted growth in the value of our brand is also supported by strong net tangible assets. The quality of the wines we have in stock (at cost) has never been higher, more valuable or saleable. The property and other hard assets of the business are all sound and well maintained.

The 2012 crop is still somewhat uncertain owing to the prolonged wet early summer. However, our vineyards and partner vineyards are well sited and well managed and suffered far less than vineyards in other parts of the country. We are cautiously optimistic that we will still manage to maintain at least last year’s crop level.

Your Board remain confident that with such a strong brand, the prospects for the company are excellent.

Paul Brett

Chairman

*Excludes the effect of the FRS20 share option accounting adjustment.

“Cushioning the Patent Impact and Preparing for Growth: Analysis of Big Pharma’s Diversification Strategies to Overcome Industry Challenges”

“Diversification is a key strategy that many pharma companies now employ to overcome the industry’s challenges, which include the genericization of key brands, a challenging payer environment and stagnate research and development (R&D) productivity,” said Marcus Bain, Ph.D., managing director of Wescadia Group. By diversifying their portfolios into markets, such as the emerging markets, consumer and animal healthcare and vaccines, companies will potentially grow their portfolios, but they will also reduce the contribution to total company sales from key pharmaceutical brands that will be genericized in the future.

“There is the general perception among industry stakeholders that pharma companies are significantly diversifying outside of branded pharmaceuticals into other markets such as consumer and animal healthcare. However, our analysis shows that most of the leading companies have not significantly diversified outside of branded pharmaceuticals (including vaccines) between 2005 and 2010,” said Bain. “We believe this shows that companies have not made substantial changes to their business model by diversifying their portfolios outside of branded pharmaceuticals during this period.”

For more information on the report or to order a copy, please visit us at www.wescadiagroup.com.

About Wescadia Group

Wescadia Group is a healthcare consultancy firm that works with life science organizations to help them achieve sustainable growth, bring innovative treatments to market and maximize the value of their assets.

“We intend to deploy the additional capacity with a vision to solidify our positions in our identified core markets including Australia, China, Taiwan, Korea, and Japan. Our commitment to have a standardized, young, and fuel efficient fleet optimizes our resources and provides better value for our guests.”

The aircraft are scheduled for delivery between 2013 and 2014, and will be operated on the airline’s expanding network in Asia Pacific, which includes the markets of Australia, China, Taiwan, Korea, Japan and its surrounding regions. These aircraft are the same model as those that AirAsia X purchased directly from Airbus, with Rolls Royce Trent 700 engines and a Maximum Take-Off Weight of 233 tons.

"ILFC is pleased to welcome AirAsia X as our new customer in the Asia Pacific region. This new partnership will support the long-haul business of AirAsia X and reinforce the airline's position in low-cost segment of the market," said ILFC Chief Executive Officer Henri Courpron.

AirAsia X will lease the six aircraft on a 10-year lease term. The leased aircraft will be reconfigured to meet AirAsia X’s existing Airbus A330-300 configuration, which consists of 12 premium flatbeds and 365 economy seats.

“These six aircraft, together with existing delivery orders from Airbus, will see AirAsia X’s growth develop, with a total of seven deliveries each in 2013 and 2014, with the aim of being the dominant market leader in the low-cost long-haul segment,” said AirAsia X CEO Azran Osman-Rani. “We intend to deploy the additional capacity with a vision to solidify our positions in our identified core markets including Australia, China, Taiwan, Korea, and Japan. Our commitment to have a standardized, young, and fuel efficient fleet optimizes our resources and provides better value for our guests.”

AirAsia X’s Co-founder and Director, Tony Fernandes commented, “AirAsia X’s partnership with ILFC will further complement the AirAsia Group’s long-term vision of developing its presence in key markets in Asia, and strengthening the connectivity between the AirAsia’s short haul and AirAsia X long haul low cost network for the benefit of passengers’ convenience. This would hopefully fulfill our pledge – Now Everyone Can Fly further.”

About AirAsia Group

AirAsia, the leading and largest low-cost carrier in Asia, services the most extensive network with 85 destinations. Within 10 years of operations, AirAsia has carried over 150 million guests and grown its fleet from just two aircraft to approximately 105. The airline today is proud to be a truly ASEAN (Association of Southeast Asian Nations) airline with established operations based in Malaysia, Indonesia, Thailand and Philippines servicing a network stretching across all ASEAN countries, China, India, Sri Lanka and Australia. AirAsia was named the World’s Best Low Cost Airline in the annual World Airline Survey by Skytrax for four consecutive years (2009, 2010, 2011, 2012).

About AirAsia X

AirAsia X is the low cost long-haul affiliate carrier that currently flies to destinations in China, Australia, Taiwan¸ Iran, Korea Japan and Nepal. The airline currently flies to 13 destinations across 7 countries and operates on a fleet of 9 Airbus A330-300s, with a seat configuration of 12 Premium Flatbeds and 365 Economy seats. The airline has carried over 7 million guests since its inception in 2007. Our vision is to further solidify our position as the global leader in low-cost, long-haul aviation and create the first global multi hub low cost carrier network along with other members of the AirAsia Group.

About ILFC

ILFC is the world’s largest independent aircraft lessor measured by number of owned aircraft. ILFC’s portfolio consists of over 1,000 owned or managed aircraft, as well as commitments to purchase 242 new high-demand, fuel-efficient aircraft and rights to purchase an additional 50 such aircraft. www.ilfc.com

About AIG

American International Group, Inc. (AIG) is a leading international insurance organization serving customers in more than 130 countries. AIG companies serve commercial, institutional, and individual customers through one of the most extensive worldwide property-casualty networks of any insurer. In addition, AIG companies are leading providers of life insurance and retirement services in the United States. AIG common stock is listed on the New York Stock Exchange and the Tokyo Stock Exchange. www.aig.com

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50371949&lang=en

De Congresleden Joseph Pitss (R-PA), Frank Wolfe (R-VA) en Christopher Smith (R-NJ) laten het volgende weten in een brief die zojuist is afgeleverd bij de EU-voorzitter Christian Ehler:

"Wij schrijven u uit bezorgdheid aangaande de integriteit van de aanhoudende pogingen van de Europese Unie om de seksuele exploitatie van kinderen en kinderpornografie te bestrijden. Aangezien deze bestrijding een belangrijke prioriteit van de EU blijft, zijn wij verontrust over de recente uitlatingen van het Nederlandse Ministerie van Justitie en Veiligheid betreffende de vervolging van de groep “Martijn” en de beschuldigingen van kindermisbruik tegen de secretaris-generaal van Justitie, Mr. Joris Demmink.

Zoals u misschien weet is de heer Demmink beschuldigd van kinderverkrachting. Er is vastgesteld dat de heer Demmink eind jaren negentig naar Turkije is gereisd om daar verschillende slachtoffers te misbruiken en te verkrachten en daarnaast dat de heer Demmink de macht van zijn positie heeft misbruikt om de aanklachten tegen hem te dwarsbomen.

De heer Demmink wordt beschuldigd van wat men zou kunnen beschouwen als kindersekstoerisme, een vorm van mensenhandel. Gezien de aard van de beschuldigingen tegen de heer Demmink en zijn invloed binnen het Ministerie van Veiligheid en Justitie, zijn wij bezorgd dat het Ministerie niet in staat zal zijn om de Nederlandse verantwoordelijkheden zoals overeengekomen in het EU- besluit 2004/68/JHA, het raamwerkbesluit tegen de bestrijding van het seksuele misbruik van kinderen, voldoende na te komen..."

Shared Hope International en The Rebecca Project werken samen om de wereld bewust te maken van de noodzaak om de bedreiging van de kinderen van de wereld door de daders van seksueel kindermisbruik en handel serieus te nemen en het zoeken van gerechtigheid voor de slachtoffers van Joris Demmink. De heer Demmink heeft onderzoek weten te ontlopen, hetgeen ernstige vragen oproept over de bereidheid van overheden om mensenhandel te bestrijden en kinderen te beschermen die het slachtoffer zijn geworden van seksueel misbruik in hun land en in die landen waar hun burgers als sekstoerist naartoe reizen.

Contactpersoon: Janet Fallon op telefoonnummer O: 703.469.3766, M: 703.625.2532, of proptionsdc@gmail.com, voor interviews met:
Shared Hope International
Linda Smith (Amerikaans Congres 1995-99), oprichter en Voorzitter
The Rebecca Project for Human Rights
Imani Walker, Executive Director en Kwame Fosu, Policy Director

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal welke als enige juridische geldigheid beoogt.

The details, including timing and allocation of the donation, will be determined with consideration for local circumstances.

Toshiba Information Equipment Philippines, Inc. (TIP), a Toshiba group company in the Philippines, is located in Laguna province, where a large number of evacuation centers have been set up. TIP has delivered about 2,000 bags of relief supplies, containing rice, canned food, water, etc., to evacuees in vicinal community.

Toshiba Group sincerely hopes for the earliest possible recovery from this disaster.